4/A: Ionis Pharmaceuticals EVP C. Frank Bennett Amends Form 4 After Stock Sale
SEC Filing
C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals, amended a previous Form 4 filing to correct the number of shares sold on February 2, 2024.
Summary
- C. Frank Bennett, an EVP and Chief Scientific Officer at Ionis Pharmaceuticals, filed an amended Form 4 with the SEC.
- The amendment corrects the number of shares sold on February 2, 2024, which was initially reported as 1,853 restricted stock units but has been revised to reflect the actual amount of shares sold.
- On February 2, 2024, Bennett sold 1,885 shares of Ionis Pharmaceuticals common stock at a weighted average price of $49.5156 per share.
- The sales occurred in multiple transactions with prices ranging from $49.51 to $49.53.
- Following the reported transaction, Bennett beneficially owns 79,047 shares of Ionis Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing correcting a previous error, so the sentiment is neutral.
Industry Context
This filing is a routine disclosure related to insider trading activity and provides transparency to the market regarding the transactions of company executives.
Stakeholder Impact
- The amended filing ensures accurate information is available to shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 02/02/2024 | Date of original transaction and initial Form 4 filing. |
| 02/02/2024 | Date of amended filing. |
| 09/04/2024 | Date of signature on the amended Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.